223 related articles for article (PubMed ID: 32636328)
1. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
Buron MD; Chalmer TA; Sellebjerg F; Barzinji I; Danny B; Christensen JR; Christensen MK; Hansen V; Illes Z; Jensen HB; Kant M; Papp V; Petersen T; Prakash S; Rasmussen PV; Schäfer J; Theódórsdóttir Á; Weglewski A; Sorensen PS; Magyari M
Neurology; 2020 Aug; 95(8):e1041-e1051. PubMed ID: 32636328
[TBL] [Abstract][Full Text] [Related]
2. Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.
Sorensen PS; Kopp TI; Joensen H; Olsson A; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 May; 50():102813. PubMed ID: 33578207
[TBL] [Abstract][Full Text] [Related]
3. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
Chalmer TA; Kalincik T; Laursen B; Sorensen PS; Magyari M;
J Neurol; 2019 Feb; 266(2):306-315. PubMed ID: 30515628
[TBL] [Abstract][Full Text] [Related]
4. Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
Hänninen K; Viitala M; Atula S; Laakso SM; Kuusisto H; Soilu-Hänninen M
J Neurol; 2022 Feb; 269(2):913-922. PubMed ID: 34170403
[TBL] [Abstract][Full Text] [Related]
5. The effect of timing of high-efficacy therapy on processing speed performance in multiple sclerosis.
Labiano-Fontcuberta A; Costa-Frossard L; Sainz de la Maza S; Rodríguez-Jorge F; Chico-García JL; Monreal E
Mult Scler Relat Disord; 2022 Aug; 64():103959. PubMed ID: 35717900
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
7. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
9. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
Kalincik T; Diouf I; Sharmin S; Malpas C; Spelman T; Horakova D; Havrdova EK; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Jokubaitis V; van der Walt A; Grand'Maison F; Sola P; Ferraro D; Shaygannejad V; Alroughani R; Hupperts R; Terzi M; Boz C; Lechner-Scott J; Pucci E; Van Pesch V; Granella F; Bergamaschi R; Spitaleri D; Slee M; Vucic S; Ampapa R; McCombe P; Ramo-Tello C; Prevost J; Olascoaga J; Cristiano E; Barnett M; Saladino ML; Sanchez-Menoyo JL; Hodgkinson S; Rozsa C; Hughes S; Moore F; Shaw C; Butler E; Skibina O; Gray O; Kermode A; Csepany T; Singhal B; Shuey N; Piroska I; Taylor B; Simo M; Sirbu CA; Sas A; Butzkueven H;
Neurology; 2021 Feb; 96(5):e783-e797. PubMed ID: 33372028
[TBL] [Abstract][Full Text] [Related]
10. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
JAMA Neurol; 2021 Oct; 78(10):1197-1204. PubMed ID: 34398221
[TBL] [Abstract][Full Text] [Related]
11. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
[TBL] [Abstract][Full Text] [Related]
12. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Palace J; Duddy M; Bregenzer T; Lawton M; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Dobson C
Lancet Neurol; 2015 May; 14(5):497-505. PubMed ID: 25841667
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
Buron MD; Chalmer TA; Sellebjerg F; Frederiksen J; Góra MK; Illes Z; Kant M; Mezei Z; Petersen T; Rasmussen PV; Roshanisefat H; Hassanpour-Kalam-Roudy H; Sejbæk T; Tsakiri A; Weglewski A; Sorensen PS; Magyari M
Neurology; 2019 Apr; 92(16):e1811-e1820. PubMed ID: 30877188
[TBL] [Abstract][Full Text] [Related]
15. Relapses add to permanent disability in relapsing multiple sclerosis patients.
Koch-Henriksen N; Sørensen PS; Magyari M
Mult Scler Relat Disord; 2021 Aug; 53():103029. PubMed ID: 34116481
[TBL] [Abstract][Full Text] [Related]
16. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
[TBL] [Abstract][Full Text] [Related]
17. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
18. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
20. Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Müller J; Roos I; Kalincik T; Lorscheider J; Galli E; Benkert P; Schädelin S; Sharmin S; Einsiedler M; Hänni P; Schmid J; Kuhle J; Derfuss T; Granziera C; Ziemssen T; Siepmann T; Yaldizli Ö
Brain Behav; 2024 May; 14(5):e3498. PubMed ID: 38688877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
